P3 Health Partners (PIII)
(Delayed Data from NSDQ)
$0.50 USD
0.00 (0.14%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.49 -0.01 (-2.91%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.50 USD
0.00 (0.14%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.49 -0.01 (-2.91%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth A Momentum C VGM
Zacks News
P3 Health Partners (PIII) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
P3 Health Partners (PIII) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
P3 Health Partners (PIII) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, P3 Health Partners (PIII) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
P3 Health Partners Inc. (PIII) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
P3 Health Partners (PIII) delivered earnings and revenue surprises of -87.50% and 4.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Privia Health (PRVA) Q2 Earnings Expected to Decline
by Zacks Equity Research
Privia Health (PRVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will P3 Health Partners Inc. (PIII) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
P3 Health Partners (PIII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Buy Hims & Hers (HIMS) Stock Ahead of Q2 Earnings?
by Debanjana Dey
Continued solid uptake of Hims & Hers (HIMS) offerings and expanding subscriber base are likely to have driven its performance in the second quarter.
P3 Health Partners Inc. (PIII) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
P3 Health Partners (PIII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Info Systems Stocks to Buy as Industry Rebounds
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Clover Health Investments (CLOV), Talkspace (TALK) and P3 Health Partners (PIII) are expected to gain from the new normal trends.
Zacks Industry Outlook Highlights P3 Health Partners, Talkspace and Augmedix
by Zacks Equity Research
P3 Health Partners, Talkspace and Augmedix are pat of the Zacks Industry Outlook article.
3 Medical Info Systems Stocks to Buy as Industry Trends Improve
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like P3 Health Partners (PIII), Talkspace (TALK) and Augmedix (AUGX) are expected to gain from the new normal trends.
Here's Why P3 Health Partners Inc. (PIII) is Poised for a Turnaround After Losing -28.57% in 4 Weeks
by Zacks Equity Research
P3 Health Partners Inc. (PIII) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here Is Why Bargain Hunters Would Love Fast-paced Mover P3 Health Partners Inc. (PIII)
by Zacks Equity Research
P3 Health Partners Inc. (PIII) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.